Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Carcinoids of the lung are a wide range of tumors with various malignancy.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Gurevich L, Voronkova I, Ashevskay V, Bondarenco E, Fedorov D,
Keywords: lung, carcinoid, immunophenotype,
Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Markovich A, Kuznetsova A, Gorbunova V, Orel N, Emelianova G,
Keywords: neuroendocrine tumors, everolimus, uni- and multivariate analysis,
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Isiangulova A, Khasanov R,
Keywords: neuroendocrine tumors, somatostatin analogues, target therapy, everolimus, systemic therapy,
Introduction: Diagnostics and management of patients with neuroendocrine tumors of the lung requires an individual approach
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Gurevich L, Korsakova N, Voronkova I, Kazantseva I, Ashevskaya V,
Keywords: lungs, neuroendocrine tumors, somatostatin receptor, differentiation,
Introduction: The majority of all NETs develop in the GI tract and about one third develop in the lungs; approximately 43% and 51% of pts, respectively, are diagnosed with adv disease (regional or distant metastasis). While GI and lung NETs are rare, their incidence has increased markedly over the past four decades. The severe and progressive nature of adv NET suggests significant costs for pts and payers.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Gaasvik L, Aavikko M, Kurki S, Oddershede L,